3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
12
Withdrawn
2
Not yet recruiting
2
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
47
Genitourinary
43
Other hematologic neoplasm
12
Plasma cell
7
Myeloid
2
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Dendritic Cell Sarcoma, Interdigitating
1
Interventions
Cyclophosphamide
26
Temozolomide
23
Doxorubicin
22
Radiotherapy
21
Filgrastim
19
Ifosfamide
15
pazopanib
14
Gemcitabine
14
Etoposide
13
Bevacizumab
13
Irinotecan
12
Cisplatin
12
Magnetic Resonance Spectroscopy
11
Imatinib Mesylate
11
Granulocyte Colony-Stimulating Factor
11
Carboplatin
11
Radiation
9
Methotrexate
9
pembrolizumab
8
fludarabine phosphate
8
Rituximab
8
Paclitaxel
8
Docetaxel
8
Cyclosporine
8
Busulfan
8
Antilymphocyte Serum
8
fludarabine
7
Vincristine
7
Radiotherapy, Intensity-Modulated
7
Mycophenolic Acid
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Prednisone
×
Sarcoma
×
Clear all
NCT02531308
2022-09-28
DLBCL
Rush University Medical Center
Phase 2
Terminated
5 enrolled
5 charts